2024. Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in the Phase 3 Clinical Trials in Psoriasis, POETYK PSO-1 and PSO-2: Time to Meaningful Improvements in Itch as Assessed by the Psoriasis Symptoms and Signs Diary. SKIN The Journal of Cutaneous Medicine. 8, 2 (Mar. 2024), s358. DOI:https://doi.org/10.25251/skin.8.supp.358.